U.S. Markets closed
  • S&P Futures

    4,704.00
    +2.50 (+0.05%)
     
  • Dow Futures

    35,830.00
    +19.00 (+0.05%)
     
  • Nasdaq Futures

    16,494.75
    +13.50 (+0.08%)
     
  • Russell 2000 Futures

    2,365.40
    +1.20 (+0.05%)
     
  • Gold

    1,861.20
    -0.20 (-0.01%)
     
  • Silver

    24.88
    -0.02 (-0.08%)
     
  • EUR/USD

    1.1369
    -0.0006 (-0.0568%)
     
  • 10-Yr Bond

    1.5890
    -0.0150 (-0.94%)
     
  • Vix

    17.59
    +0.48 (+2.81%)
     
  • GBP/USD

    1.3497
    -0.0003 (-0.0216%)
     
  • USD/JPY

    114.3040
    +0.0520 (+0.0455%)
     
  • BTC-USD

    57,832.39
    +3,263.77 (+5.98%)
     
  • CMC Crypto 200

    1,402.14
    -65.80 (-4.48%)
     
  • FTSE 100

    7,255.96
    -35.24 (-0.48%)
     
  • Nikkei 225

    29,683.09
    +84.43 (+0.29%)
     

Solid Biosciences Stock Gains After Duchenne Dystrophy Gene Therapy Data

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Solid Biosciences Inc (NASDAQ: SLDB) reports 1.5-year functional data and patient-reported outcome measures in the ongoing IGNITE DMD Phase 1/2 trial of SGT-001.

  • SGT-001 is a novel adeno-associated viral (AAV) vector-mediated gene transfer therapy for Duchenne muscular dystrophy (DMD).

  • The data will be presented today at the World Muscle Society 2021 Virtual Congress.

  • The data demonstrated durable expression and function of microdystrophin protein after 12 to 24 months post-dosing.

  • Related Content: Solid Bio's DMD Gene Therapy Shows Promising Early Data, No New Safety Concerns, But Fails To Cheer Investors.

  • NSAA scores (measurement of functional motor abilities) showed minimal change compared with baseline and suggested benefit after treatment compared to trajectories typically observed in natural history data.

  • Natural history analyses suggest that patients would usually exhibit a 4.5-point decline in NSAA over 1.5 years.

  • In contrast, patients exhibited a mean decrease of 1.7 points from baseline and a mean difference of +2.8 points compared with natural history data.

  • 6-Minute Walk Test (6MWT) distances were maintained 1.5 years post-dosing, while natural history analyses suggested a 63.5-meter decline.

  • The mean increase in the 6MWT was 15.3 meters compared with baseline, and the mean difference compared with natural history data was +78.8 meters.

  • The percent predicted FVC (lung function tests) continued to show stability or improvement, while natural history analyses suggest a decline of 7.5%.

  • Patient-reported outcome measures showed meaningful, sustained improvements at 1.5 years compared with baseline.

  • No new drug-related safety findings were reported.

  • Price Action: SLDB stock is up 1% at $3.03 during the market session on the last check Thursday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.